BRISTOL-MYERS SQUIBB ACQUIRES LIPHA GLUCOPHAGE MARKETING RIGHTS
Executive Summary
BRISTOL-MYERS SQUIBB ACQUIRES LIPHA GLUCOPHAGE MARKETING RIGHTS in the U.S. for the pending product for treatment of non- insulin dependent diabetes mellitus (NIDDM) or Type II diabetes, the company announced April 27. Financial terms of the agreement, which is effective immediately, were not disclosed. In exchange, Lipha gains marketing rights in France to BMS's once-a-day ACE inhibitor fosinopril (Monopril) for the treatment of hypertension and congestive heart failure. The Lyon, France-based company will receive marketing rights to additional unnamed BMS products in Europe at a later date, BMS said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth